Dikla Akselbrad - PolyPid Chief Officer
| PYPD Stock | USD 3.34 0.12 3.47% |
Insider
Dikla Akselbrad is Chief Officer of PolyPid
| Age | 51 |
| Address | 18 Hasivim Street, Petah Tikva, Israel, 4959376 |
| Phone | 972 7 4719 5700 |
| Web | https://www.polypid.com |
PolyPid Management Efficiency
The company has return on total asset (ROA) of (0.6465) % which means that it has lost $0.6465 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.9662) %, meaning that it created substantial loss on money invested by shareholders. PolyPid's management efficiency ratios could be used to measure how well PolyPid manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 11.96, whereas Return On Tangible Assets are forecasted to decline to (1.63). At present, PolyPid's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 7 M, whereas Non Currrent Assets Other are forecasted to decline to about 82.7 K.Similar Executives
| Showing other executives | INSIDER Age | ||
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Dale Christensen | Tff Pharmaceuticals | N/A | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| Paul Manley | Tff Pharmaceuticals | N/A | |
| BS CPA | Inhibrx | 42 | |
| Glenn Mattes | Tff Pharmaceuticals | 67 | |
| Andreas EMBA | Molecular Partners AG | 58 | |
| , MBA | Molecular Partners AG | 51 | |
| Quinn Deveraux | Inhibrx | N/A | |
| Susan MS | Eliem Therapeutics | N/A | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| MBA MD | Eliem Therapeutics | 63 | |
| Anthony Hickey | Tff Pharmaceuticals | N/A | |
| Seth Lewis | Molecular Partners AG | N/A | |
| Mark Lappe | Inhibrx | 57 | |
| Harlan Weisman | Tff Pharmaceuticals | 72 | |
| Patrick Amstutz | Molecular Partners AG | 49 | |
| James JD | Eliem Therapeutics | 58 | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Kirk Coleman | Tff Pharmaceuticals | 50 | |
| Robert MBA | Eliem Therapeutics | 56 | |
Management Performance
| Return On Equity | -4.97 | ||||
| Return On Asset | -0.65 |
PolyPid Leadership Team
Elected by the shareholders, the PolyPid's board of directors comprises two types of representatives: PolyPid inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PolyPid. The board's role is to monitor PolyPid's management team and ensure that shareholders' interests are well served. PolyPid's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PolyPid's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ori Warshavsky, Chief US | ||
| Dikla Akselbrad, Chief Officer | ||
| Malka Reichart, Scientific Director | ||
| Rivi Levari, Vice Resource | ||
| Orna Blum, Legal Counsel | ||
| JeanMarc PharmD, Chief Officer | ||
| Tal Vilnai, General Secretary | ||
| Dalit Hazan, Executive Affairs | ||
| Jonny Missulawin, Chief Officer | ||
| Evgeny Valdman, Ex Operations | ||
| Maria Rubin, Vice Operations |
PolyPid Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PolyPid a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -4.97 | ||||
| Return On Asset | -0.65 | ||||
| Current Valuation | 23.21 M | ||||
| Shares Outstanding | 6.8 M | ||||
| Shares Owned By Insiders | 24.24 % | ||||
| Shares Owned By Institutions | 36.74 % | ||||
| Number Of Shares Shorted | 13.01 K | ||||
| Price To Book | 10.53 X | ||||
| EBITDA | (20.26 M) | ||||
| Net Income | (23.86 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether PolyPid is a strong investment it is important to analyze PolyPid's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact PolyPid's future performance. For an informed investment choice regarding PolyPid Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PolyPid. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade PolyPid Stock refer to our How to Trade PolyPid Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PolyPid. If investors know PolyPid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PolyPid listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.22) | Return On Assets (0.65) | Return On Equity (4.97) |
The market value of PolyPid is measured differently than its book value, which is the value of PolyPid that is recorded on the company's balance sheet. Investors also form their own opinion of PolyPid's value that differs from its market value or its book value, called intrinsic value, which is PolyPid's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PolyPid's market value can be influenced by many factors that don't directly affect PolyPid's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PolyPid's value and its price as these two are different measures arrived at by different means. Investors typically determine if PolyPid is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PolyPid's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.